Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Exondys

- PMLiVE

FDA unveils new biosimilars guidance

Will clarify route to market for copies of biological drugs

- PMLiVE

Following the biologic path

Biosimilar regulations in Canada, the US and Europe all have a degree of uncertainty

- PMLiVE

Boehringer lines up biosimilars of major drugs

Prospects include copies of Humira, Avastin and MabThera

- PMLiVE

Herceptin could face biosimilars in UK later this year

Court overturns patents protecting Roche’s cancer drug

- PMLiVE

Biosimilars: friend or foe for healthcare systems?

An opportunity in Europe, but widespread acceptance and uptake is by no means a done deal

- PMLiVE

Merck KGaA appoints biosimilar head

Simon Sturge joins from Boehringer Ingelheim

- PMLiVE

Merck joins biosimilar Lantus race

Will work with Samsung to develop version of Sanofi's diabetes medicine

- PMLiVE

Roche blocks Herceptin biosimilar in India

Wins court battle after claiming Biocon and Mylan had not followed regulatory criteria

Sanofi reception

Sanofi sues Lilly over insulin patents

Challenges development of Lantus biosimilar

- PMLiVE

Global biosimilars market “will see exponential growth”

Report predicts market to grow to $23bn by 2019

- PMLiVE

Biocon plans February launch for first biosimilar Herceptin

Set to market own version of breast cancer drug in India

Biogen Idec building

Biogen Idec licenses anti-TNF biosimilars

Treatment prospects emerge from joint venture with Samsung Biologics

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links